Weekly Digest – December 2025 Weekly Digest – December 2025 25 December 2025: Enhertu approved in China as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer following disease progression after one or more […]
Weekly Digest – December 2025 Weekly Digest – December 2025 23 December 2025: GSK Korea, first approval of multiple myeloma treatment ‘Blenrep’ ADC GSK Korea received regulatory approval from Korea’s Ministry of Food and Drug Safety for Blenrep (Belantamab mafodotin), […]
Weekly Digest – December 2025 Weekly Digest – December 2025 22 December 2025: Enhertu granted breakthrough therapy designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received its tenth FDA Breakthrough […]
Weekly Digest – December 2025 Weekly Digest – December 2025 22 December 2025: PeptiDream announces FDA clearance of IND applications for Phase 1 clinical trials of 225Ac-PD-32766 and 64Cu-PD-32766 in patients with kidney Cancer PeptiDream received U.S. Food and Drug […]
Weekly Digest – December 2025 Weekly Digest – December 2025 22 December 2025: Simcere Zaiming builds exclusive partnership with Ipsen for Simcere Zaiming’s innovative antibody drug conjugate Simcere Zaiming and Ipsen entered an exclusive licensing partnership granting Ipsen global rights outside Greater China to develop, manufacture, and […]
Weekly Digest – December 2025 Weekly Digest – December 2025 22 December 2025: Tongyi Pharmaceuticals announced that it has entered into an exclusive licensing agreement with MultiValent Biotherapies for CBP-1018, a peptide-drug conjugate for the treatment of prostate cancer Tongyi Pharmaceuticals entered an […]
